Cellectis

Cellectis is a genome engineering company developing genetic medicines for diseases that today demand a lifetime of treatment.

[Cellectis @cellectis]

Et si une seule administration permettait de traiter à la source certaines maladies cardiométaboliques sévères ?
André Choulika était l'invité de @bfmbusiness pour échanger sur les nouvelles perspectives ouvertes par l'édition du génome: https://t.co/w65LBFEQvP

[Cellectis @cellectis]

Pourquoi arrêter un programme clinique qui venait d’obtenir le statut RMAT de la FDA ?

André Choulika répond dans Le Journal des Biotechs de @Boursorama. Il y explique la transformation de Cellectis en société d’édition du génome in vivo >>
https://t.co/IfGFDVz38E

[Cellectis @cellectis]

Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company.

To read the press release: https://t.co/T6w0cllnZ9

[Cellectis @cellectis]

Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update.

To read the press release: https://t.co/bZmvieIVH6

[Cellectis @cellectis]

@cellectis announces participation in upcoming investor conferences.

To read the press release: https://t.co/wIMqgGrskQ

[Cellectis @cellectis]

Cellectis Reports Financial Results for the Second Quarter 2026.

To read the press release:
https://t.co/y7k731WcBO

[Cellectis @cellectis]

#Cellectis to Report Second Quarter Financial Results on August 6, 2026.

Full press release here: https://t.co/vMyBXGJi4Q

[Cellectis @cellectis]

Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026.

Read the full press release here: https://t.co/EduInV6CLW

[Cellectis @cellectis]

Today at #EHA2026, we shared final Ph1 results from BALLI-01, evaluating lasme-cel in patients with r/r B-ALL.
*100% ORR in the target Ph2 population (n=7)
*All responding patients proceeded to transplant
*Manageable safety profile
Full press release: https://t.co/8xJPo2CRO4

[Cellectis @cellectis]

Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL.

To read the press release: https://t.co/7OftnIXCgN

[Cellectis @cellectis]

#Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026.

Full press release here : https://t.co/7TZLsbhKRZ

[Cellectis @cellectis]

Cellectis announced two presentations at the @EHA_Hematology
>> Lasme-cel - Oral presentation | June 13
>> Eti-cel - Poster presentation | June 13
To read the press release: https://t.co/E9kp3FlNoC

[Cellectis @cellectis]

Cellectis Reports Financial Results for the First Quarter 2026.

To read the press release: https://t.co/BcMmdbyUpk

[Cellectis @cellectis]

Cellectis to report first quarter financial results on May 11, 2026.

to read the press release: https://t.co/vlPmQHnLGD

[Cellectis @cellectis]

Cellectis presents epigenetic editing platform to turn genes off without altering DNA at the American Society of Gene & Cell Therapy annual meeting. #ASGCT2026

To read the press release: https://t.co/XdSiG7aUbX

[Cellectis @cellectis]

@cellectis highlights today's interim Phase 2 data for cema-cel. Cema-cel was originally developed by Cellectis as UCART19, the first allogeneic CAR-T program we ever built. Congrats to the teams at Allogene & Servier!

To read the press release: https://t.co/HdsNugA1FK

[Cellectis @cellectis]

@cellectis Reports Full Year 2025 Financial Results and Provides a Business Update.
To read the press release: https://t.co/UptOp5J9aL

[Cellectis @cellectis]

📢 Save the Date: @cellectis will report Q4 & FY 2025 results on March 19
🗓️ Mar 19 (Post-market): Earnings Release
🗓️ Mar 20 (8:00AM ET / 1:00PM CET): Earnings Call
Join the webcast here: https://t.co/mmIl4US6BW

#Biotech #Earnings

[Cellectis @cellectis]

Et si le temps n'était plus l'ennemi du patient ? ⏳

Pour un cancer agressif, chaque minute est un combat. Un traitement "sur étagères" est : déjà produit, congelé et prêt à l'emploi >> l'interview d'@AChoulika sur @bfmbusiness à 08:48min: https://t.co/wzhvvt0p2A

[Cellectis @cellectis]

From Paris 🇫🇷 to New York 🇺🇸 to Raleigh 🇺🇸: One Team, One Mission.🎗️

On #WorldCancerDay, we celebrate 26 years of pioneering gene editing. We aren’t just building treatments, we are engineering the end of the wait for patients.

Together, we edit the future.